Michigan Medicine enters drug discovery collaboration with AstraZeneca in Chronic Kidney Disease

ANN ARBOR—Patients with Chronic Kidney Disease (CKD) may benefit from a new collaboration between the University of Michigan (U-M) and AstraZeneca who have partnered to develop a new therapeutic strategy for treatment. The partners will jointly conduct chemistry and drug discovery research with the aim of developing candidate drugs. 

Read the full story from Michigan Medicine.